Stelios Papadopoulos - 14 Mar 2024 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Director
Signature
Christopher Aker, Attorney in Fact
Issuer symbol
RGLS
Transactions as of
14 Mar 2024
Net transactions value
+$400,000
Form type
4
Filing time
15 Mar 2024, 16:19:09 UTC
Previous filing
14 Aug 2023
Next filing
17 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGLS Common Stock Award $400,000 +250,000 +34% $1.60 978,388 14 Mar 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated March 11, 2024, with a closing date of March 14, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof.